diabetes insulin sensitivity
Conditions
Interventions
Overnight infusion of placebo, low and high dose UAG before an oral GTT the
following morning
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: • Female or Male subject of 18 years of age or older; • Documented diagnosis of type 2 diabetes as defined by American Diabetes Association; • Diagnosis of type 2 diabetes for at least 3 months prior to screening; • Metformin monotherapy for at least 3 months prior to screening is allowed • Screening HbA1c between 6.5% and 8.5%; • Body Mass Index between 25 and 35 kg/m2;
Exclusion criteria
Exclusion criteria: • History of or presence of active concomitant conditions or disease that would interfere with the protocol conduct and study assessments, as judged by the investigator; • History or presence of long-term type 2 diabetes complications; • Clinically significant abnormalities in laboratory evaluation at screening, as judged by the investigator; • Use of systemic corticosteroids within 60 days prior to screening; • If female, pregnancy or breast feeding; • Drug or alcohol dependence or abuse; • Participation in a trial of an experimental drug or device within 60 days prior to screening
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Glucose levels | — |
Countries
Netherlands
Outcome results
None listed